tissues, except at a very low concentration (0.044 ng/mg) in the liver, suggesting a very low risk 50 of systemic toxicity of locally delivered ATV. Additionally, the ex vivo data showed that ATV in 51 solution permeates through isolated human saphenous veins and thus is a good candidate for 52 perivascular delivery. 53
Intimal hyperplasia (IH) is the major cause of grafted vessel occlusion and occurs frequently 34 after bypass intervention. No pharmaceutical formulation is currently available to prevent this 35 pathology. Local perivascular delivery of an appropriate active compound released in a time-36 dependent manner (from day one up to 4 weeks) is necessary for an efficient single-37 administration preventive therapy. To this aim, we propose the combination of gel and 38 microparticles delivery system containing atorvastatin (ATV). The incorporation of ATV in a 39 cross-linked hyaluronic acid gel, provided in vitro a fast release over 3 days, while ATV-loaded 40 poly-lactic-co-glycolic acid (PLGA) microparticles dispersed in the gel gave a sustained release 41 over 4 weeks. In vivo, ATV formulations were applied perivascularly in mice undergoing carotid 42 artery ligation. IH was significantly reduced (-68 %) in presence of ATV incorporated in 43 hyaluronic acid gel and encapsulated in microparticles compared to control. No significant IH 44 alteration in IH was observed when ATV was incorporated only in the gel (fast release) or only 45 in the microparticles (slow release) demonstrating that a biphasic release of ATV is essential to 46
interfere with the development of IH. 47
ATV was detected in adjacent tissues 28 days after the intervention, showing the 48 sustained presence of the drug in vivo. After four weeks ATV was not detected in remote 49
tissues, except at a very low concentration (0.044 ng/mg) in the liver, suggesting a very low risk 50 of systemic toxicity of locally delivered ATV. Additionally, the ex vivo data showed that ATV in 51 solution permeates through isolated human saphenous veins and thus is a good candidate for 52 perivascular delivery. 53
Introduction 60
Despite the improved results of endovascular treatment (balloons, stents), open surgical 61 revascularization remains the gold standard for the treatment of vascular occlusive diseases. It 62 is performed in over one million patients per year worldwide [1] . Autologous saphenous vein 63 graft is the conduit of choice for peripheral bypasses. However, graft failure may occur within up 64 to five years following the intervention, leading to a redo surgery, amputation and increased 65 mortality rate [2] . Indeed, the combination of hemodynamic factors, such as turbulent blood flow 66 due to a mismatch between graft and artery mechanical properties as well as surgical 67 manipulation, result in a progressive lumen occlusion due to cell proliferation (restenosis) [3] . 68
This clinical occurrence is mainly driven by intimal hyperplasia (IH), which is the thickening of the 69 inner layer of the vessel due to vascular smooth muscle cell (VSMCs) migration and proliferation 70 as well as high extracellular matrix secretion ( 
Quantifying microparticle drug loading 145
Approximately 4 mg of microparticles were dissolved in 3 mL of acetonitrile. Then, 3 mL of 146 ethanol were added to ensure ATV dissolution. The samples were analyzed by reversed phase 147 HPLC (LC module I plus, Waters corporation, Milford, USA), and ATV was measured with a UV 148 spectrometer set at  = 245 nm, retention time 7.8 min. The column was a Nucleosil CC 125 / 4 149 120-5 C 18 (Macherey-Nagel GmbH & Co. KG, Oensingen, Switzerland), maintained at 25°C.The 150 mobile phase was 55 % acetate buffer (10 mM, pH 3) and 45 % acetonitrile, at a flow rate 151 1ml/min. The calibration curve was constructed by consecutive dilutions of ATV in 152 acetonitrile/ethanol containing PLGA (0.781, 1.56, 3.13, 6.25, 12.5, 25.0, 50.0 µg/ml). The 153 method has been fully validated, and a limit of quantification of 500 ng/mL and limit of detection 154 of 50 ng/mL were obtained. A trueness of 98 to 102 % was determined, and the intermediate 155 precision was 2 %; moreover, the three replicates injected on three different days demonstrated 156 the repeatability of the method. The quantification was conducted in triplicate. The results are 157 presented as actual drug loading, corresponding to the percent mass ratio of the encapsulated 158 drug to the mass of the microparticles recovered. 159
Incorporation of microparticles and/or ATV in the gel 160
Freeze dried particles were dispersed in water. ATV was dissolved in a hydroalcoholic 161 solution of 30 % ethanol. The gel was mixed with the suspension of microparticles (94 mg per 162 gram of gel) and/or ATV in solution using a spatula and immediately freeze-dried in a Telstar 163 LyoBeta 15 (Telstar, Terrassa, Spain) with primary drying at -40 °C under 0.2 mBar for 10 h 164 followed by 10 h of secondary drying at 20 °C. Prior to use, the cake was re-hydrated with a 165 sufficient amount of sterile water to obtain the initial weight. To minimize the microbial load, the 166 preparation was performed in a hood under laminar flow (Steag LFH 07.15, Luftechnik + 167 Metallbau AG, Wettingen, CH), solutions were filtered prior to use and glassware was sterilized. 168
The commercial clHA gel was sterile. ATV-loaded gels are referred to as Gatv and unloaded 169 gels as G. 170
171
The composition of the various formulations is presented in Table 1 . The GatvMatv was 172 prepared by merging the amounts of ATV contained in Gatv and the microparticles Matv. 173 Table 1 . Amount of ATV loaded in the gel and/or the microparticle formulations applied in vivo. 174 G: gel, M: microparticles, Gatv: gel containing free ATV, Matv: microparticles encapsulating ATV 175
Scanning electron microscopy 176
For microscopic observations, an atorvastatin ethanolic solution (50 % w/v) was lyophilized 177
and rehydrated with distilled water at a concentration of 1 mg/mL. Particles were suspended in 178 distilled water. A drop of the suspension was placed onto stubs, dried under vacuum, covered 179 with a 15 -20 nm layer of gold and examined by scanning electron microscopy (SEM) using a 180 JSM -7001FA (JEOL, Tokyo, Japan) at 5.0 kV. To obtain microparticles cross-sections, dry 181 particles were immersed in common wood glue and cut using a razor blade. These sections 182 were further processed as mentioned above. 183
Rheological measurements 184
The rheology of the preparations described in Table 1 ; clHA as received or after lyophilization 185 (G) and Poloxamer 407 at 20 % w/w were characterized at 37 o C with a Haake Rheostress 1, 186
Thermo Scientific fitted with a 35 mm / 2 o cone-plate geometry. The instrument was set to 187 perform the measurements with three repetitions and deliver the results as the mean. Rotation 188 was performed over a shear rate ranging from 0.01 to 500 s -1 . Oscillation was performed with a 189 frequency ranging from 0.628 to 31.4 rad/sec. 190
Swelling measurements 191
Approximately 50 mg of clHA or Poloxamer 407 were allowed to swell in MilliQ water at 192 (DKK Italia). In total 68 animals were used (sham n=8, GM n=18, GatvM n=8, GMatv n=8, 233
GatvMatv n=18, healthy n=8). 234
Common carotid arteries were harvested bilaterally from the mice at sacrifice (28 days), 235 fixed in formalin and paraffin-embedded. To observe the IH formation, the left and right carotid 236 arteries were transversely sectioned in 6-µm thick cuts at 0.1 mm from the ligation. Hematoxylin 237 and eosin (HE) as well as Van Gieson Elastin (VGEL) staining were performed for histologic and 238 morphometric analysis. A Panoramic MIDI slide scanner (3DHistech Kft., Hungary) was used to 239 digitize the sections. Snapshots were extracted using Panoramic Viewer software. Upon first 240 observation of the sections, about 10% of the slides showed the presence of thrombi, therefore, 241 these samples were not taken into account. For intimal and medial thickness, as the intima is not 242 always homogenous in thickness, 72 measurements (12/cross section on 6 cross sections) were 243 performed as recently published [39] . Neointima thickness was defined as the distance between 244 the lumen and the internal elastic membrane. For each carotid artery, the intima and media 245 thickness were measured. The media thickness was defined as the distance between the 246 internal elastic lamina and the external elastic lamina. Similar methodology and measurements 247 were performed on contralateral carotids. Each carotid section was divided by a 2x2 grid. The 248 thicknesses of intima and media were defined as the mean of the thickness of four 249 measurements, randomly chosen in each square of the grid. 250
For immunofluorescence, five-micrometer sections of carotids were prepared from 251 paraffin-embedded tissues. In brief, after deparaffinization and heat-mediated antigen retrieval, 252 sections were incubated with a primary antibody against SMA (rabbit polyclonal, ab5694; Abcam 253 1:100), in combination with biotinylated CD31 (rat polyclonal; 553371; BD Pharmingen, 1:100) in 254 blocking buffer (PBS, 2% BSA, 0.3% Triton X-100) at 4°C overnight. Samples were then 255 incubated for 1 h at room temperature with either Alexa-Fluor-594-or -488-coupled secondary 256 antibodies (Life Technologies), diluted 1:500 in PBS, covered with PBS containing 50% glycerol 257 and 0.4μg/mL DAPI, and observed by fluorescence microscopy (Leica Leitz DMRB, Nidau, 258 Switzerland). Two controls, in which we omitted the primary or secondary antibody, were 259 included in each experiment. 260
At sacrifice at 28 days, we collected adjacent tissues (thymus, sternocleidomastoid 261 muscle, and neck skin) as well as remote tissues (biceps femoris muscle, heart, lungs and liver). 
Ex vivo permeability model 286
Four segments of non-varicose human great saphenous veins (hGSV) were used under 287 patient written consent. The hGSV were cut longitudinally and mounted on a watertight Franz's 288 diffusion cell (intima facing the receptor compartment). In total, 11 pieces of hGSV were 289 obtained. The medium used to fill the Franz's diffusion cells was RPMI 1640 containing 5 % fetal 290 bovine serum (Gibco, Life Technologies) and 1 % antibiotic-antimycotic solution (10,000 U/mL 291 penicillin G, 10 mg/mL streptomycin sulfate, 25 mg/mL amphotericin B, and 0.5 μg/mL 292 gentamycin). Four-hundred microliters of ATV (16 μg/mL) in solution in the medium were placed 293 in the donor compartment. The receptor compartment was filled with 1 mL of medium and was 294 kept under magnetic agitation at 37° C and 5 % C0 2 . 295
At predetermined time intervals (1 h, 24 h, 36 h, 48 h, 60 h, 72 h), 50 µL of culture medium 296
with medium and stored at -80ᵒ C to measure the ATV concentration. The concentration of ATV 300 in tissue was measured by LC/MS-MS as described above. 301
The hGSVs were fixed in formalin before and after being mounted on Franz's diffusion cell. 302
They were then transversely sectioned in 6-µm thick cuts and stained with HE and VGEL. 303
Histomorphometric analysis was performed as described above 304 2.12.
Statistical analyses 305
All statistical analyses were performed using GraphPad Prism 6.05. Outliers were removed by 306 ROUT Q = 1 %. 307
In vivo histomorphometry 308
Ordinary one-way ANOVA with Tukey's multiple comparison test was performed to compare the 309 groups. 310
Biodistribution 311
A two-tailed Mann-Whitney t-test was performed to compare GMatv and GatvMatv groups for 312 adjacent tissues. 313
Ex vivo permeation 314
A two-tailed Mann-Whitney t-test was performed to compare vein content in ATV at 24h and 315 72h. Ordinary one-way ANOVA with Dunn's multiple comparison test compared donor content in 316 ATV at 0h, 24h and 72h. 317
Results 318
We prepared three different formulations to evaluate the most efficient treatment for IH. 319
These formulations had various release profiles in vitro: a) fast release within a few days, b) 320 sustained release over several weeks, and c) combination of fast and sustained release. A 321 control formulation was also prepared containing an unloaded gel and microparticles. 322
Preparation and characterization of the formulations 323
The microscopic and macroscopic aspects of the formulations are shown in Fig. 3 . After 324 dispersion in water and drying, ATV was in the form of a nanosuspension of amorphous 325 filaments (Fig 3a) . Spherical PLGA microparticles of a mean diameter of 15 μm (span = 1.453) 326
were obtained. Their cross-sections had a plain, matrix aspect (insert in Fig 3b) . The ATV actual 327 drug loading was 1.5 ± 0.18 % (w/w). 328
Poloxamer 407 as a frequently used excipient for gel formulation was included in the early 329 tests. Poloxamer 407 at 20 % w/w and clHA had a similar appearance at 37 o C (Fig. 3 c and d) . 330
The clHA lost its transparency after lyophilization and became opaque when ATV and/or 331 microparticles were incorporated (Fig. 3 f-h) . Table 2 ). The weak elasticity of the poloxamer 407 exhibited a ten-fold 342 higher tan(δ) value compared to clHA. Little swelling potential was observed for poloxamer 407 343 compared to clHA. 344
The viscosity of the gel decreased with the incorporation of the ATV ethanolic solution 345 (GatvM) or increased when microparticles were added in absence of ATV in the gel (GM, 346
GMatv). For all of the formulations, excepted for the poloxamer, the elastic properties were 347 practically unaltered as the viscosity modulus (G'') remained well below the elastic one (G') 348 throughout the measurement (tan(δ) < 1) 349 350 
In vitro drug release profile 356
The three formulations presented different release kinetics in vitro (Fig. 4) . ATV diffused 357 out of GatvM within 3 days (fast release). GMatv release extended over 4 weeks (sustained 358 release). It showed a triphasic release profile with a lag time between seven and twelve days. 359
GatvMatv demonstrated a combination of a fast release (60 % of ATV) in the first 3 days and a 360 sustained release over 4 weeks. The GatvMatv curve was similar to the curve obtained by the 361 addition of the data from GatvM and GMatv, as indicated by the similarity factor f2 ˃ 50. 
In vivo efficacy on the CAL model 371
The in vivo efficacy of the formulations containing ATV (GatvM, GMatv, GatvMatv) was 372 compared to the unloaded gel and microparticles (GM) on a carotid artery ligation model of mice 373 generating IH. Controls comprised sham operated and healthy mice. Four of 68 mice were found 374 dead a few hours after the operation due to internal bleeding. Five mice presented luminal 375 thrombi on histological sections and were excluded from the measurements. After 28 days, the 376 gel and microparticles applied perivascularly were still observed (Fig. 2, lower right panel) . No 377 evidence of ATV toxicity such as necrosis was observed macroscopically. 378
Representative histological samples of carotid artery sections are presented in Fig. 5 . In 379 the sham mice, we observed the presence of the typical hyperplasic disordered arrangement of 380
VSMCs on the sub-intimal area of the vessel (Fig. 5) . The intimal thickness increased up to 381 almost complete occlusion of the lumen in the carotids for these animals. The intima/media ratio 382 alteration for GM (+5 %, p > 0.9999) and GatvM (-24 %, p = 0.941) showed no significant 383 difference compared to sham operated animals. When microparticles encapsulating ATV were 384 present in the formulation (GMatv), the intima/media ratio decreased compared to sham 385 operated animals (-39 % p = 0.6840). However, the values reached significance only for 386 GatvMatv, when ATV was added in the gel and was at the same time encapsulated in the 387 microparticles (-68 %, p = 0.0415). The intima/media ratio of the animals treated with GatvMatv 388 formulation was not significantly different from the one observed with healthy mice (p = 0.7490). 389
The preservation of the endothelial cell lining in the vessel wall was demonstrated (Fig. 6) . The presented as the mean values of 7 to 8 animals, except from GM and GatvMatv, for which 16-17 400 animals were used. Each bar is the mean ± SEM. Ordinary one-way ANOVA with Tukey's 401 multiple comparisons: P < 0.05 (*), P < 0.01 (**) compared to the sham. P < 0.01 (++), P < 0.001 402 (+++), compared to GM. P < 0.05 (#), P < 0.01 (##), P < 0.001(###) compared to healthy mice. 403 The concentration of ATV was quantified in tissues adjacent to the site of application such 411 as the thymus gland, neck skin and sternocleidomastoid muscle (Fig. 7) . We detected 0.5 to 3.2 412 ng of ATV per mg of tissue in animals treated with gels containing ATV-loaded microparticles 413 (GMatv, GatvMatv). ATV was below the detection limit for GM and GatvM formulations. ATV was 414 not detected in remote tissues such as biceps femoris, heart, lungs and serum. In the liver, we 415 
Ex vivo diffusion of ATV through human saphenous veins 426
We investigated the diffusion of ATV in solution through a hGSV wall using a Franz's cell 427 set-up. First, we evaluated the microstructural changes of the tissue after 3 days of exposure to 428 high ATV concentrations (Fig. 8, upper panel) . No microscopic alteration was observed on the 429 vessel wall in terms of nuclei integrity and overall organization both for VSMCs and endothelial 430 cells. ATV in the donor compartment gradually diffused through the vein wall and was detected 431 in the receptor compartment (Fig. 8, lower panel) (light grey), human vein (grey) and receptor (black) compartments. Amounts of ATV are written 441 in the bar. Each bar is the mean ± SD (n=11). Two-tailed Mann-Whitney t-test gave no 442 significant difference between vein content in ATV at 24h and 72h. Ordinary one-way ANOVA 443 with Dunn's multiple comparison test for donor content in ATV showed P < 0.05 between 0h 444 and 24h, and P < 0.001 between 0h and 72h. No significant difference was observed between 445 24h and 72h. 446
Discussion 447
The aim of this study was to explore the potential of a single administration of an ATV 448 formulation to prevent the development of IH, which is responsible for bypass graft failure. The 449 local perivascular route of administration was selected. We address the preparation and the in 450 vivo test of a drug delivery system containing ATV gathering the following components: a) a 451 clHA gel for the ease of application, slow biodegradability [27], a proven track record of safety in 452 humans providing a fast release of ATV; b) PLGA microparticles for providing sustained drug 453 release kinetics; and c) atorvastatin as the active compound, which permeates the vein and 454 reduces VSMC proliferation and migration [35] . (Table 2) . Non-elastic gel is also prone to flow away from the site of 463 application. Additionally, these gels are known to rapidly dissolve in vivo [41] , precluding their 464 use for our goal of a release kinetic from day 0 to day 28. 465
Thus, we selected a cross-linked gel that would remain in vivo for the long term. 466
Commercially available clHAs are used in rheumatology (Synvisc ® ), ophthalmology (Anikavisc ™ ) 467 and for aesthetic interventions (Fortélis Extra ® ). Due to their cross-linked nature, the residence 468 time of these formulations in vivo can extend from hours to months. In the present study, the 469 clHA gel was still detected at the site of application 28 days after the intervention (Fig. 2) . This 470 finding is consistent with its elastic rheological behavior (Table 2) . 471
A sustained release strategy is crucial for the prevention of IH, that was shown to progress 472 up to 49 days after intervention in an arteriovenous polytetrafluoroethylene graft model [42] . In 473 fact, the acute stage of IH development occurs during the first 30 days following the intervention 474 [1] . As clHA doesn't offer the possibility of delivering the drug for a long period of time (Fig. 4  475 GatvM), PLGA microparticles were added in the gel. Zhu Unfortunately, these non-cross-linked gels, which were used as matrices for particle support, are 479 known to wash away rapidly. Moreover, it was also mentioned that a series of injections might 480 be necessary to maintain an effective drug concentration [21] . 481
To determine the optimal release kinetics inhibiting IH, formulations were ranked as "fast" (Fig. 5 and 6 ). The formulations varied in efficacy in 498 vivo (Fig. 5) .We observed that unloaded clHA and microspheres had no effect on inhibiting IH. 499
The literature on this topic is controversial, as some studies report that HA is able to reduce IH 500 formation [46, 47] , had no effect [48] , or an increased cellular response was observed [49] . In 501 these studies, the types and concentrations of HA gels vary, and thus, a case by case study 502 should be performed to conclude on the efficacy of HA over IH. 503
The most efficient ATV loaded formulation in vivo was the combination of a fast and 504 sustained release (GatvMatv). GatvM had little effect in decreasing the development of IH. This 505 might be related to the short time frame during which ATV is available in the proximity of the 506 carotid artery (3 days in vitro). ATV-loaded microparticles (GMatv) showed a higher anti-507 restenotic effect (-39 % I/M) compared to GatvM (-24 %), suggesting that a sustained release is 508 mandatory for the formulation to be efficient. The in vitro release profile of GatvMatv is the sum 509 of the release profiles of GatvM and GMatv (Fig. 4) . However, in vivo, IH prevention effect of 510 GatvMatv (I/M ratio 0.32) was higher than the effect observed with GatvM (I/M ratio 0.76) 511 combined with the effect of (I/M ratio 0.61) in absence of any interaction (combination effect I/M 512 ratio 0.46, corresponding to a 54% decrease). This suggests that the concomitant presence of 513 ATV in both gel and microparticles leads to a synergistic rather than an additive effect as a 68% 514 decrease was observed in the presence of ATV in gel and microparticles. 515
The efficacy of the combined formulation is thought to be related to the time course of the 516 development of IH which progresses mainly as a hyperacute (hours to days) and acute stages 517 (days to weeks) [42, 50] . Indeed, the release profile of GatvMatv matches this time course well; 518 a) a high amount of ATV is made available within the first few days to prevent the high 519 proliferation rate of VSMC on the media and the adventitia and b) when the migration of the 520 VSMC and subsequent proliferation takes over later as a constant amount of ATV is delivered 521 from the microparticles. 522
In vitro, we previously established that the EC50 of ATV for the proliferation and migration 523 of hVSMCs is 10 ng/μL [35] . The amounts that were detected in adjacent tissues in vivo 4 weeks 524 after local administration of formulations GMatv, GatvMatv are in the same order of magnitude 525 (Fig. 7) . Such high ATV concentration is 3 order of magnitude higher than the ATV plasma 526 concentration typically obtained after oral administration [51] . Instead, the maximum plasma 527 concentration achieved after oral administration is 0.01 ng/μL [51] . Therefore, only a local 528 formulation can achieve high, bioactive ATV concentrations. 529
These high local concentrations of ATV may raise concerns for potential local toxicity. 530
Particularly, the endothelial lining could be affected, generating life-threatening thrombogenic 531 events. We showed that ATV, as well as clHA and PLGA microparticles, had no destructive 532 effect on the vessel's endothelium (Fig. 6 ). As the endothelium was intact in all conditions, either 533 the endothelium is not affected by the intervention or healing occurred during the 4 weeks 534 following the intervention. These results are in agreement with the observations of Zheng et al. 535
and stress the advantages of ATV compared to cytotoxic treatments [30, 52, 53] . 536
Biodistribution data showed that ATV was not detected at day 28 in the serum, and low 537 concentrations were found in remote tissues except for the liver (Fig. 8) . Although ATV is widely 538 used in clinical practice; hepatotoxicity and severe myopathy are commonly described as side 539 effects [54]. Meanwhile, it was reported that oral doses of ATV as high as 2.5 and 5 mg/kg/day 540 are necessary to inhibit IH in animal models [31, 32, 55] . Those doses are close to the toxicity 541 zone, as an administration of 10 mg/kg/day demonstrated extensive liver necrosis in rabbits. 542 Therefore, local administration limits the risk of systemic toxicity by reducing the drug distribution 543 in remote tissues after four weeks. In this study, mouse tissues were macroscopically intact 544 upon harvesting. Even for the ex vivo model, when the tissues were exposed to an extremely 545 high ATV concentration, no structural alteration was observed on hGSV histological sections 546 (Fig. 8) . 547
The rodent model employed has the disadvantage of slim vasculature compared to human 548 vasculature. As shown by Lovich & Edelman, the diffusive barrier imposed by the vessel to the 549 drug depends greatly on the adventitia thickness [56] . Thus, we had to ensure that the in vivo 550 effect on the slim mice carotids could be reproduced on thicker vessels such as the grafts used 551 for bypass interventions in humans. Therefore, we investigated the ex vivo permeation of ATV 552 through the hGSV which are the material of choice for bypass grafts. We showed that ATV 553 applied perivascularly would reach its site of action -the intimal layer -in human vessels (Fig. 8) . 554
A high concentration of ATV rapidly impregnated the hGSV after 24 h, confirming the relevance 555 of our choice of a lipophilic statin. Creel et al. who worked on the arterial distribution of paclitaxel 556 ex vivo reached a similar conclusion [57] . However, compared to our results, their 4 h-long 557 perivascular exposure of the vessel to the drug was probably not sufficient for the drug to reach 558 the intima. Our extended time course on hGSV over 3 days allows us to conclude to a slow 559 diffusion process over days. 560
Conclusion 561
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